ProHealth me-cfs Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|

Trending News

Happiness, Gratitude and Appreciation

New clinical research program to combat chronic pain and chronic fatigue syndrome

It’s Still a Wonderful Life

Lack of Knowledgeable Healthcare Access for Patients with Neuro-endocrine-immune Diseases

Survey Data on Name Change for ME/CFS Analyzed for Publication

Assessment of activity limitations and participation restrictions with persons with chronic fatigue ...

Help the National ME/FM Action Network win $5000!

Shake That *^#&! ing Stigma – The “Shake the CFS Stigma Challenge” Begins

US Disabled Hold Protests at Bethesda

Now Is the Time for a National PR Campaign for ME/CFS!

 
Print Page
Email Article

Iron deficiency predicts outcome in acute heart failure

  [ 2 votes ]   [ Discuss This Article ]
www.ProHealth.com • June 4, 2014


Press Release: European Society of Cardiology, May 17, 2014

Iron deficiency (ID), defined as a combination of depleted body iron stores and unmet cellular iron requirements, identified acute heart failure (AHF) patients with the worst outcomes, reported a Polish observational study in yesterday’s Late Breaking Trial session.

Iron is an essential micronutrient involved in cellular energy and metabolism. “In previous studies iron deficiency has been shown to be common in patients with chronic HF and to aggravate symptoms and worsen clinical outcomes,” explained study presenter Ewa Jankowska. The current study, she added, is the first to look at iron status in AHF.

Two major pools of iron are known to exist in the body: stored iron (hepatocytes, reticuloendothelial cells, and syderoblasts) and utilized iron (circulating iron and intracellular iron in virtually all cells). “Diagnosis of ID needs to take both these pools into consideration since they closely interact with each other and iron can be physiologically transferred between these departments,” explained Jankowska, from Wroclaw Medical University, Poland.

In the prospective study, 165 patients with a diagnosis of AHF as the primary cause of hospitalization had their serum hepcidin measured on admission as a marker for depleted iron stores, and serum soluble transferring receptor (sTfR) as a marker of unmet cellular iron requirements. The primary end-point was all-cause death, with 33 deaths occurring by 12 months follow-up.

Depleted body iron stores were diagnosed when serum hepcidin was <14.5 ng/ mL (the 5th percentile among healthy controls); while depleted utilized iron stores were diagnosed when serum sTfR was>1.59 mg/L (the 95th percentile among healthy controls). Four different groups of patients were defined: those with the most severe ID (low hepcidin and high sTfR); isolated low hepcidin; isolated high sTfR; and preserved iron status (neither low hepcidin nor high sTfR).

Results show iron deficiency (defined as low hepcidin and high sTfR) was demonstrated in 37% of patients (61), whereas isolated high sTfR was found in 29% (48) and isolated low hepcidin in 9 % (15). Mortality at 12 months was 41 % [95% CI 29-53%] for patients with low hepcidin and high sTfR compared to 15% [95%CI 5-25%] for patients with isolated low hepcidin levels and 0% for patients with preserved iron status (p<0.001).

“Indices of iron status were only weakly, if at all, associated with haemoglobin. Profound ID (low hepcidin and high sTfR) was seen in both anaemics and non-anaemics,” said Jankowska, adding that iron status appeared to be severely deranged as serum hepcidin levels were extremely low and serum sTfR high.

“Profound ID confirmed as depleted iron stores and iron avidity allows for the identification of AHF patients with particularly poor outcomes. This holds equally for both anaemic and non anaemic patients. Correction with iron supplementation may offer an attractive therapeutic option targeting abnormal metabolism in patients with AHF who still have unacceptably high mortality. We hope to initiate such a trial soon” said Jankowska.
 


Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Nutritional Supplement Orders

Featured Products

Hydroxocobalamin Extreme™ Hydroxocobalamin Extreme™
The B-12 your brain needs for detox & sharpness
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
B-12 Extreme™ B-12 Extreme™
The Most Potent Vitamin B-12 on Earth
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

Rejuvenating the Brain - How PQQ Helps Power Up Mental Processing Rejuvenating the Brain - How PQQ Helps Power Up Mental Processing
Reversing Neurodegeneration with a New Magnesium Compound Reversing Neurodegeneration with a New Magnesium Compound
The Big Blue Fish that Helps Chase the Blues Away The Big Blue Fish that Helps Chase the Blues Away
Sleep Like a Baby in Nature's Cradle Sleep Like a Baby in Nature's Cradle
More Weight Loss than Any Other Discovery in Supplement History More Weight Loss than Any Other Discovery in Supplement History

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia Diagnosis
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS Diagnosis
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE  |  PRIVACY
CONTACT US
LIBRARY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing